

Verisk Analytics, Inc.
Form FWP
February 27, 2019

Free Writing Prospectus

Filed pursuant to Rule 433

To Prospectus dated March 27, 2017

Preliminary Prospectus Supplement dated February 27, 2019

Registration Statement File No. 333-216966

Verisk Analytics, Inc.

\$400,000,000 4.125% Senior Notes due 2029 (the Notes)

Pricing Term Sheet

Issuer:	Verisk Analytics, Inc.
Ticker:	VRSK
Expected Rating*:	Baa2 / BBB / BBB+
Size:	\$400,000,000
Maturity:	March 15, 2029
Coupon:	4.125%
Public Offering Price:	99.463% of face amount
Yield to Maturity:	4.191%
Spread to Benchmark Treasury:	150 basis points
Benchmark Treasury:	2.625% due February 15, 2029
Benchmark Treasury Price / Yield:	99-13+ / 2.691%
Interest Payment Dates:	March 15 and September 15, commencing September 15, 2019
Redemption Provisions:	Prior to December 15, 2028, the Notes may be redeemed, in whole or in part, at a make-whole redemption price equal to the greater of:

100% of the principal amount of the Notes to be redeemed;
and

the sum of the present values of the remaining scheduled payments (as defined in the prospectus supplement) of the Notes to be redeemed, discounted to the date of redemption on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the applicable treasury rate (as defined in the prospectus supplement) plus 25 basis points;

in each case, plus accrued and unpaid interest, if any, thereon to, but excluding, the date of redemption.

On or after December 15, 2028, the Notes may be redeemed, in whole or in part, at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, thereon to the applicable redemption date.

Settlement: T+5; March 6, 2019

Denominations: \$2,000 and any integral multiple of \$1,000 above that amount

CUSIP / ISIN: 92345Y AF3 / US92345YAF34

Joint Book-Running Managers: HSBC Securities (USA) Inc.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
J.P. Morgan Securities LLC
Morgan Stanley & Co. LLC
SunTrust Robinson Humphrey, Inc.
Wells Fargo Securities, LLC

Co-Managers: BNP Paribas Securities Corp.
RBC Capital Markets, LLC
TD Securities (USA) LLC
The Williams Capital Group, L.P.

Additional Information:

We expect that delivery of the Notes will be made to investors on or about March 6, 2019, which will be the fifth New York business day following the date of this prospectus supplement (such settlement being referred to as T+5). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade Notes prior to the delivery of the Notes may be required, by virtue of the fact that the Notes initially settle in T+5, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes prior to their date of delivery should consult their advisors.

*

Note: A securities rating is not a recommendation to buy, sell, or hold securities and may be subject to revision or withdrawal at any time.

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting HSBC Securities (USA) Inc. (call 1-866-811-8049) or Merrill Lynch, Pierce, Fenner & Smith Incorporated (call 1-800-294-1322).

This communication should be read in conjunction with the Preliminary Prospectus Supplement and the accompanying base prospectus. The information in this communication supersedes the information in the Preliminary Prospectus Supplement and the accompanying base prospectus to the extent inconsistent with the information in the Preliminary Prospectus Supplement and the accompanying base prospectus.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.